Key events, in time order
argenx agrees to buy Forte for $77/share, adding anti-CD122 antibody FB102 to immunology pipeline.
Deal at $77/share cash, 40.6% premium, expands immunology pipeline; confirmed by multiple independent sources.
Multiple sources confirm Q2 product net sales of $1.52B, up 60% YoY, with strong profitability and cash flow.
None yet
None yet
Argx is highlighted for strong weekly momentum within the biotech sector, indicating a potential upward trend. The discussion focuses on its inclusion in a list of top-performing stocks.
Main discussion
IBD Top 50 Stocks $TVTX 🥇 $ETON $KNSA $TGTX $ERO $NTRA $HNGE $ATI $WT $ENVA $ECO $EXPE $HALO $GKOS $URGN $VCTR $OSCR $AUGO $AU $VIRT $ZETA $SN $SCCO $ATEYY $ARIS $NAVN $ADPT $RBRK $DXCM $WPM $ARGX $NEM $IAG $ANET $KRYS $RELY $STT $NET $SNOW $OMDA $LLY $HMY $GRMN $MU $FIVE $MGNI $
Stocks showing the strongest weekly momentum, led by standout gains across biotech, healthcare, financials, and precious metals. $MRNA $AMLX $PURR $MRVI $TEM $DRD $AMR $AU $BNTX $FIGR $CRCL $TWST $ALM $ARGX $RUM $HMY $SLS $CAI $HIMS $KGC https://t.co/LP0qGgRqZ5
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
A biotech making antibody drugs that dial down the immune system to treat autoimmune diseases like myasthenia gravis, sold globally as VYVGART.
Revenue comes from selling VYVGART and VYVGART HYTRULO, with gross margins around 90% and net margins near 33% in 2025.
Patents and complex FcRn biology protect the lead drug, but rivals like UCB and Johnson & Johnson are developing similar FcRn blockers, eroding the edge.
